RESUMO
Microdialysis is an excellent tool to assess tissue inflammation in patients, but in vitro systems to evaluate recovery of inflammatory mediators have not been standardized. We aimed to develop a reference plasma preparation and evaluate different perfusion fluids with respect to recovery of metabolic and inflammatory markers. The reference preparation was produced by incubation of human blood with lipopolysaccharide and cobra venom factor to generate cytokines and activate complement, respectively. Microdialysis with 100 kDa catheters was performed using different colloid and crystalloid perfusion fluids (hydroxyethyl starch (HES) 130/0.4, HES 200/0.5, hyperosmolar HES 200/0.5, albumin 200 g/l, T1 perfusion fluid and Ringer's acetate) compared to today's recommended dextran 60 solution. Recovery of glucose, glycerol and pyruvate was not significantly different between the perfusion fluids, whereas lactate had lower recovery in HES 200/0.5 and albumin perfusion fluids. Recovery rates for the inflammatory proteins in comparison with the concentration in the reference preparation differed substantially: IL-6 = 9%, IL-1ß = 18%, TNF = 0.3%, MCP-1 = 45%, IL-8 = 48%, MIG = 48%, IP-10 = 25%, C3a = 53% and C5a = 12%. IL-10 was not detectable in microdialysis dialysate. HES 130/0.4 and HES 200/0.5 yielded a recovery not significantly different from dextran 60. Hyperosmolar HES 200/0.5 and albumin showed significantly different pattern of recovery with increased concentration of MIG, IP-10, C3a and C5a and decreased concentration of IL-1ß, TNF, MCP-1 and IL-8 in comparison with dextran 60. In conclusion, microdialysis perfusion fluid dextran 60 can be replaced by the commonly used HES 130/0.4, whereas albumin might be used if specific immunological variables are in focus. The present reference plasma preparation is suitable for in vitro evaluation of microdialysis systems.
Assuntos
Citocinas/metabolismo , Inflamação/diagnóstico , Leucócitos Mononucleares/imunologia , Microdiálise/métodos , Perfusão , Albuminas/metabolismo , Células Cultivadas , Proteínas do Sistema Complemento/metabolismo , Venenos Elapídicos/metabolismo , Humanos , Derivados de Hidroxietil Amido/metabolismo , Inflamação/imunologia , Mediadores da Inflamação/metabolismo , Lipopolissacarídeos/metabolismo , Microdiálise/normas , Plasma/metabolismo , Padrões de ReferênciaRESUMO
We developed a live Escherichia coli model of acute sepsis in pigs with emphasize on biomarkers reflecting the early inflammatory response of sepsis. Healthy pigs, 25-35 kg, were challenged intravenously (IV) (n = 12) or intrapulmonary (n = 6) with live E. coli and observed for 3 and 5 h respectively. Control pigs received culture medium (n = 6 + 3). Haemodynamic parameters and a broad panel of inflammatory mediators were measured. The dose of bacteria was carefully titrated to obtain a condition resembling the early phase of human septic shock. The IV group displayed a pro-inflammatory response [significant increase in tumour necrosis factor-alpha, interleukin (IL)-6 and IL-8] and an early anti-inflammatory response (significant increase in IL-10). For the first time, we demonstrate a significant increase in IL-12 and matrix metalloproteinase-9 (MMP) early in pig sepsis. Coagulation was activated (significant increase in thrombin-antithrombin complexes) and there was a significant decrease in the serum proteins suggesting capillary leakage. Haemodynamic parameters reflected a septic condition with significant decrease in systemic blood pressure, increases in heart rate, pulmonary artery pressure and base deficit. None of these changes was observed in the control group. Interleukin-1beta and vascular endothelial growth factor increased in both groups. Nitric oxide measurements suggested an initial pulmonary vascular endothelial inflammatory response. The intrapulmonary group, which did not resemble septic condition, showed a substantial increase in MMP-9. In this porcine model of sepsis, IL-12 and MMP-9 were detected for the first time. These biomarkers may have an impact in the understanding and future treatment of sepsis.
Assuntos
Biomarcadores/sangue , Mediadores da Inflamação/sangue , Sepse/sangue , Sepse/fisiopatologia , Animais , Modelos Animais de Doenças , Escherichia coli , Hemodinâmica , Interleucina-12/sangue , Metaloproteinase 9 da Matriz/sangue , Sepse/imunologia , SuínosRESUMO
The potential of autologous bone marrow transplantation to improve the treatment results for patients with small cell lung cancer (SCLC) may be limited by the presence of tumor cells in the graft. We constructed immunotoxins (ITs) involving 4 monoclonal antibodies and Pseudomonas exotoxin A and investigated the cytotoxicity of the ITs to H-146 SCLC cells in the presence and absence of normal human bone marrow (BM) cells. The Pseudomonas exotoxin A conjugate with the MOC-1 antibody, which recognizes an NCAM antigen, was inactive, as tested in a reproducible soft agar assay. Conjugates involving the monoclonal antibodies MOC-31, NrLu10, and MLuC1 killed about 3.5 log tumor cells at 0.1 microgram/ml and > 5.0 log at 1 microgram/ml. In the absence of BM cells, the combination of the 3 ITs was not superior to each IT used individually. However, when H-146 cells were admixed to nucleated BM cells at the ratio of 1:10, > 5 log tumor cell kill was obtained at a concentration as low as 0.1 microgram/ml of each IT. Survival of normal BM progenitor cells was only moderately reduced by the IT treatment, even in experiments in which the 3 IT3s were used at 2.5 micrograms/ml each. Freezing and thawing of the BM, as required in a clinical setting, reduced the colony-forming unit, granulocyte-macrophage, and colony-forming unit, granulocyte-erythroid-macrophage-megakaryocyte, by 30-60% in both treated and untreated cultures. We conclude that the use of a mixture of the 3 ITs provides a safe, rapid, and effective method for eradicating SCLC cells from BM used for autologous bone marrow transplantation following high-dose chemotherapy.
Assuntos
Purging da Medula Óssea , Carcinoma de Células Pequenas/patologia , Exotoxinas , Neoplasias Pulmonares/patologia , Pseudomonas , Ensaio de Unidades Formadoras de Colônias , Criopreservação , HumanosRESUMO
Three monoclonal antibodies reactive with antigens abundantly expressed on human carcinoma cells were used to develop and compare the efficacy of immunotoxins (ITs) and immunobeads for purging breast cancer cells from bone marrow. ITs constructed as conjugates of the monoclonal antibodies and Pseudomonas exotoxin A showed high specific cytotoxicity against three breast cancer cell lines, inhibiting protein synthesis by 50% at concentrations of 4 x 10(-13) M to 1 x 10(-10) M. Tested in a reproducible clonogenic assay, two of the ITs used at a concentration of 0.1 microgram/ml killed > 5 log units of MCF7 cells, the maximal sensitivity for assessing cytotoxic effects, and 1.5 log of T-47D tumor cells. At 1 microgram/ml, each of the three ITs eliminated > 5 log of both cell lines. The immunobead procedure removed 2.0-4.1 log of tumor cells with one purging cycle and up to 6.0 log with two cycles. The mixture of the three ITs or immunobeads was not clearly superior in efficacy, compared to the use of individual molecules, probably reflecting an overlap in expression of the respective antigens in these cell lines. For both methods, the purging efficacy was not reduced when the tumor cells were admixed with normal bone marrow cells at a ratio of 1:10. The survival of colony-forming units, granulocyte/macrophage, was 49-86% with the immunobeads and 44-75% even at high concentrations (up to 2.5 micrograms/ml x 3) of the ITs. The results indicate that each of the two immunological methods can be safely used for effective elimination of tumor cells from the graft of breast cancer patients undergoing autologous bone marrow transplantation.
Assuntos
Antígenos de Neoplasias/imunologia , Purging da Medula Óssea/métodos , Neoplasias da Mama/terapia , Endotoxinas/imunologia , Epitopos/imunologia , Imunotoxinas/imunologia , Pseudomonas , Anticorpos Monoclonais/imunologia , Neoplasias da Mama/imunologia , Sobrevivência Celular , Feminino , Humanos , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Células Tumorais CultivadasRESUMO
Conditions for removing B-lymphoma cells from human bone marrow using "immunobeads" (IBs) were investigated. The IBs were prepared by coupling monoclonal antibodies directly to a new type of monodisperse magnetic polymer particles (M 450). Two monoclonal immunoglobulin M antibodies, AB-1 (CD 19), a B-cell-specific antibody, and AB-4, an HLA-DR-specific antibody, were used. The IBs were incubated with Rael Burkitt lymphoma cells admixed to fresh, mononuclear human bone marrow cells. After incubation for 30 min at 4 degrees C, the IBs were removed using cobalt samarium magnets. The number of remaining clonogenic tumor cells was assayed by the Courtenay and Mills soft agar procedure, and the clonogenic capacity of the bone marrow progenitor cells was measured by granulocyte-monocyte and granulocyte-erythroid-monocyte-megakaryocyte assays. With a ratio of tumor cells to normal bone marrow cells of 0.1 or 0.01 and a ratio of immunobeads to tumor cells in excess of 75, a tumor cell depletion of more than 3 logs was achieved with the AB-4 IBs and slightly less with the AB-1 beads. After two consecutive cycles of purification with the AB-4 beads, no colonies were found, corresponding to more than 6 logs of purification. In the case of the AB-1 beads, 4 to 5 logs of purification were achieved. The concomitant reduction in clonogenic bone marrow progenitor cells was only 30 to 40%. Flow cytometric studies showed that the tumor cell population contained appreciable proportions of cells binding only small amounts of the antibodies used. The results indicate that the IB procedure is highly efficient and capable of removing tumor cells expressing low levels of antigen. Compared to other purging methods in use the procedure described seems to offer several advantages with respect to efficacy, speed, and simplicity. By the use of a panel of suitable antibodies the new immunobead procedure may be potentially useful in autologous bone marrow transplantation of B-lymphomas and non-T-leukemias with poor prognosis.
Assuntos
Anticorpos Monoclonais , Medula Óssea/patologia , Linfoma/patologia , Linfócitos B/citologia , Linfócitos B/ultraestrutura , Linfoma de Burkitt/patologia , Linfoma de Burkitt/ultraestrutura , Linhagem Celular , Separação Celular/métodos , Ensaio de Unidades Formadoras de Colônias , Humanos , Linfoma/ultraestrutura , Magnetismo , Microscopia Eletrônica de VarreduraRESUMO
Many centers use CY and G-CSF to mobilize PBPC. In this study we explored whether a standard chemotherapy regimen consisting of mitoguazon, ifosfamide, MTX and etoposide (MIME) combined with G-CSF was capable of mobilizing PBPC in lymphoma patients. Twelve patients with Hodgkin's disease (HD) and 38 patients with non-Hodgkin's lymphoma (NHL) were mobilized with MIME/G-CSF. Most patients were heavily treated with different chemotherapy regimens receiving a median of 11 cycles (range 3 to 20) of chemotherapy prior to mobilization. It was found that the optimal time of PBPC harvest was at days 12 and 13 after initiating the mobilization regimen. The median number of collected CD34+ cells per kg body weight was 7.1 x 10(6) (range 0.5-26.2). More than 2.0 x 10(6) CD34+ cells/kg were achieved in 69% of the patients after one apheresis. When additional cycles of apheresis were done, only 6% failed to harvest this number of CD34+ cells. There was a statistically significant inverse correlation between the number of prior chemotherapy cycles and CD34+ cell yield (P = 0.003). No such association was found between CD34+ cell yield and prior radiotherapy. When MIME/G-CSF was compared with Dexa-BEAM/G-CSF, it was found that MIME/G-CSF tended to be more efficient in mobilizing PBPC in spite of being less myelotoxic. All patients transplanted with MIME/G-CSF mobilized PBPC had fast and sustained engraftment. These results demonstrate that an ordinary salvage chemotherapy regimen, such as MIME combined with G-CSF can be successfully used to mobilize PBPC.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Fator Estimulador de Colônias de Granulócitos/administração & dosagem , Mobilização de Células-Tronco Hematopoéticas/métodos , Transplante de Células-Tronco Hematopoéticas , Doença de Hodgkin/tratamento farmacológico , Doença de Hodgkin/terapia , Linfoma não Hodgkin/tratamento farmacológico , Linfoma não Hodgkin/terapia , Adolescente , Adulto , Carmustina/administração & dosagem , Terapia Combinada , Citarabina/administração & dosagem , Dexametasona/administração & dosagem , Etoposídeo/administração & dosagem , Feminino , Sobrevivência de Enxerto , Células-Tronco Hematopoéticas/efeitos dos fármacos , Doença de Hodgkin/sangue , Humanos , Ifosfamida/administração & dosagem , Linfoma não Hodgkin/sangue , Masculino , Melfalan/administração & dosagem , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Mitoguazona/administração & dosagem , Terapia de Salvação , Fatores de TempoRESUMO
Exposing blood to an artificial surface results in a systemic inflammatory response, including cytokine release and complement activation. We studied the artificial surface-induced inflammation in human whole blood using an extensive panel of inflammatory mediators including proinflammatory cytokines, chemokines and growth-factors and investigated the role of the complement system in the induction of this response. Using multiplex technology, 27 different inflammatory mediators were measured after circulating blood for 4 hours in polyvinyl chloride tubing. The C3 inhibitor compstatin was used to block complement activation. A significant (p < 0.05) increase in 14 of the 27 mediators was induced by the surface, of which 7 were chemokines (IL-8, MCP-1, MIP-1alpha, MIP-1beta, RANTES, eotaxin and IP-10) and 5 were growth-factors (G-CSF, GM-CSF, VEGF, PDGF and FGF). The traditional proinflammatory cytokines like IL-1beta, TNFalpha and IL-6 were not induced, although IL-6, as well as IL-15 and IL-17 increased if the surface was coated with highly bioincompatible laminaran. Inhibition of complement activation with compstatin significantly (p < 0.05) reduced the formation of 12 of the 14 mediators. For 10 of the 12 mediators, the inhibition was by 2/3 or more, for the remaining two the inhibition was more moderate. A highly biocompatible heparin-coated PVC surface was used as negative control and completely abolished the whole inflammatory response. The artificial surface PVC markedly induced a broad spectrum of chemokines and growth-factors, which was largely dependent on activation of complement.
Assuntos
Quimiocinas/efeitos dos fármacos , Ativação do Complemento/efeitos dos fármacos , Citocinas/efeitos dos fármacos , Inflamação/induzido quimicamente , Peptídeos Cíclicos/farmacologia , Cloreto de Polivinila/farmacologia , Anticoagulantes/farmacologia , Quimiocinas/sangue , Complemento C3/antagonistas & inibidores , Complemento C3/efeitos dos fármacos , Citocinas/sangue , Glucanos , Heparina/farmacologia , Humanos , Polissacarídeos/farmacologiaRESUMO
Microdialysis emerges as a useful tool to evaluate tissue inflammation in a number of clinical conditions, like sepsis and transplant rejection, but systematic methodological studies are missing. This study was undertaken to determine the recovery of relevant inflammatory mediators using the microdialysis system, comparing microdialysis membranes with two different molecular weight cut-offs at different flow rates. Twenty and 100 kDa pore sizes CMA microdialysis catheters were investigated using velocities of 0.3, 1.0 and 5.0 microl/min. Reference preparations for cytokines [tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6 and IL-10; m.w. 17-28 kDa] and chemokines (IL-8, MCP-1, IP-10 and MIG; m.w. 7-11 kDa) were prepared from plasma after incubating human whole blood with lipopolysaccharide. Reference preparation for complement anaphylatoxins (C3a, C4a, C5a; m.w. 9-11 kDa) was prepared by incubating human plasma with heat-aggregated immunoglobulin G. The reference preparations were quantified for the respective inflammatory molecules and used as medium for the microdialysis procedure. Through the 20 kDa filter only the four chemokines passed, but with low recovery (3-7%) and limited to the 1.0 microl/min velocity. The recovery with the 100 kDa filter was as follows: IL-1beta = 75%, MCP-1 = 55%, MIG = 50%, IL-8 = 38%, C4a = 28%, IP-10 = 22%, C5a = 20%, C3a = 16%, IL-6 = 11, IL-10 = 8% and TNF-alpha = 4%. The highest recovery for all chemokines and anaphylatoxins were consistently at velocity 1.0 microl/min, whereas IL-1beta and IL-10 recovered most efficiently at 0.3 microl/min. Thus, microdialysis using catheters with a cut-off of 100 kDa is a reliable method to detect inflammation as judged by a defined panel of inflammatory markers. These findings may have important implications for future clinical studies.
Assuntos
Anafilatoxinas/análise , Líquidos Corporais/química , Citocinas/análise , Inflamação/sangue , Microdiálise/métodos , Cateterismo/instrumentação , Citocinas/sangue , Humanos , Mediadores da Inflamação/análise , Mediadores da Inflamação/sangue , Microdiálise/instrumentaçãoRESUMO
The pathophysiology of meconium aspiration syndrome (MAS) is complex. We recently showed that meconium is a potent activator of complement. In the present study, we investigated whether the complement activation occurring in experimental MAS is associated with a systemic inflammatory response as judged by granulocyte activation and cytokine and chemokine release. MAS was induced by the instillation of meconium into the lungs of newborn piglets (n = 8). Control animals (n = 5) received saline under otherwise identical conditions. Haemodynamic and lung dynamic data were recorded. Complement activation, revealed by the terminal sC5b-9 complex (TCC), and cytokines [interleukin (IL)-6 and IL-8] were measured in plasma samples by enzyme immunoassays. The expression of CD18, CD11b and oxidative burst in granulocytes was measured in whole blood by flow cytometry. Plasma TCC increased rapidly in the MAS animals in contrast with controls (P < 0.0005). The TCC concentration correlated closely with oxygenation index (r = 0.48, P < 0.0005) and ventilation index (r = 0.57, P < 0.0005) and inversely with lung compliance (r = -0.63, P < 0.0005). IL-6 and IL-8 increased in MAS animals compared with the controls (P = 0.002 and P < 0.001, respectively). Granulocyte oxidative burst declined significantly in the MAS animals compared with the controls (P < 0.02). TCC correlated significantly with IL-6 (r = 0.64, P < 0.0005) and IL-8 (r = 0.32; P = 0.03) and inversely with oxidative burst (r = -0.37; P = 0.02). A systemic inflammatory response associated with complement activation is seen in experimental MAS. This reaction may contribute to the pathogenesis of MAS.
Assuntos
Ativação do Complemento , Síndrome de Aspiração de Mecônio/complicações , Síndrome de Aspiração de Mecônio/imunologia , Síndrome de Resposta Inflamatória Sistêmica/etiologia , Síndrome de Resposta Inflamatória Sistêmica/imunologia , Animais , Animais Recém-Nascidos , Citocinas/biossíntese , Modelos Animais de Doenças , Granulócitos/imunologia , Granulócitos/metabolismo , Humanos , Recém-Nascido , Pulmão/fisiopatologia , Síndrome de Aspiração de Mecônio/fisiopatologia , Explosão Respiratória , Sus scrofa , Síndrome de Resposta Inflamatória Sistêmica/fisiopatologiaRESUMO
High dose chemotherapy with autologous bone marrow transplantation (ABMT) has shown promise in several types of cancer. There is, however, a risk of transfusing contaminating tumour cells with the bone marrow cells, e.g. in patients with small cell lung carcinoma (SCLC). To eliminate SCLC cells from normal human bone marrow, four monoclonal antibodies reactive with SCLC cells were used with immunomagnetic beads in model experiments. With two cycles of immunomagnetic elimination the individual antibodies removed 2.5-4.4 log of H-146 tumour cells from a single cell suspension, as assessed in a highly reproducible soft agar assay. Different combinations of two antibodies were only marginally more effective than the individual MAbs, whereas 5-6 log removal was obtained with a combination of all four antibodies. The method was equally effective when the tumour cells were mixed with bone marrow cells at a ratio of 1:10. The immunomagnetic procedure did not significantly affect the survival of normal progenitor cells, assessed in CFU-GM and CFU-GEMM assays. The results indicate that the procedure safely and effectively can be used to eliminate tumour cells from the bone marrow in conjunction with ABMT in patients with SCLC.
Assuntos
Anticorpos Monoclonais , Células da Medula Óssea , Purging da Medula Óssea/métodos , Carcinoma de Células Pequenas/patologia , Neoplasias Pulmonares/patologia , Células-Tronco/citologia , Separação Celular/métodos , Células Clonais , Humanos , Técnicas Imunológicas , Magnetismo , Células Tumorais CultivadasRESUMO
The binding profile of 17 monoclonal antibodies (MAbs) to small lung cancer cell lines and normal bone marrow and peripheral blood cells was studied by immunocytochemistry and flow cytometry. At antibody concentrations that stained PJD tumour cells, only four MAbs (MOC1, MOC31, NrLu10, 81A6) were devoid of cross-reactivity with normal cells, whereas significant binding to subtypes of bone marrow and blood cells was seen for 13 antibodies. For the eight most promising MAbs the binding to ten SCLC cell lines was moderate to strong in 47 MAb/cell line combinations, and low or insignificantly in 33 combinations. Three cell lines lacked antigen for all MAbs studied. Flow cytometry was significantly less sensitive than immunocytochemistry in assessing MAb binding to both normal and tumour cells. The antigen expression was for several MAbs higher in exponentially growing tumour cells than in cells in stationary growth phase. Seven of the MAbs, which originally showed low to moderate cross-reactivity with normal cells, were titrated down to the lowest concentrations at which they stained H-146 tumour cells with high levels of antigen expression. At these concentrations five (MLuC1, Oat-1, SM-1, NCC-Lu-243, LAM2) of the seven Mabs showed acceptably low binding to bone marrow cells. At optimal concentrations altogether four to nine of the 17 antibodies studied may be used to detect tumour cell involvement in bone marrow of SCLC patients.
Assuntos
Anticorpos Monoclonais , Medula Óssea/imunologia , Neoplasias Ósseas/diagnóstico , Carcinoma de Células Pequenas/imunologia , Neoplasias Pulmonares/diagnóstico , Antígenos de Superfície/biossíntese , Células Sanguíneas/imunologia , Neoplasias Ósseas/secundário , Divisão Celular/fisiologia , Células Cultivadas , Reações Cruzadas , Citometria de Fluxo , Expressão Gênica , Humanos , Imuno-Histoquímica , Neoplasias Pulmonares/imunologiaRESUMO
BACKGROUND: Reduced body temperature is a common companion to trauma/haemorrhage. Several clinical studies have identified hypothermia as an independent risk variable predisposing to increased morbidity and mortality. At the same time it is known that most enzymatic reactions are downregulated at temperatures below 37 degrees C. Theoretically this should restrain the inflammatory response and protect the host from remote organ injury. The study was performed to test this hypothesis. METHODS: Twenty-six male Sprague Dawley rats were used for the experiments. Volume controlled haemorrhagic shock was induced by withdrawal of 2.5 ml blood/100 g body weight over 10 min. Half of the animals (n=13) were then cooled to 32.5-33 degrees C, the other half (n=13) were kept normothermic (37.5+/-0.5 degrees C). Seventy-five minutes after initiation of bleeding, two-thirds of the blood was retransfused. Thereafter the rats were observed for 2 h. Key substances of systemic inflammation were determined (plasma values of TNF-alpha, IL-6, IL-10, and corticosterone; reactive oxygen species in peritoneal phagocytes), plasma markers of organ function and integrity (AST, ALT, alphaGST, creatinine, urea), and survival. RESULTS: Hypothermia reduced the release of IL-6 (P<0.01). The reductions of plasma levels of TNFalpha (P=0.07) and IL-10 (P=0.09) were less clear-cut. The release of reactive oxygen species diminished (P<0.01). Organ injury was ameliorated, as reflected by decreased levels of AST (P<0.01), alphaGST (P<0.01), and creatinine (P<0.01). Both groups experienced an almost identical increase of plasma corticosterone. None of the hypothermic rats died, compared to two normothermic. CONCLUSION: Moderate hypothermia had an organ protective effect in this model of controlled haemorrhagic shock. This coincided with a significant reduction of the proximal cytokine IL-6 and reactive oxygen species, which conceivably influenced the outcome.
Assuntos
Hipotermia Induzida , Inflamação/prevenção & controle , Choque Hemorrágico/imunologia , Animais , Hemodinâmica , Sistema Hipotálamo-Hipofisário/fisiologia , Interleucina-10/sangue , Interleucina-6/sangue , Medições Luminescentes , Masculino , Sistema Hipófise-Suprarrenal/fisiologia , Ratos , Ratos Sprague-Dawley , Choque Hemorrágico/complicações , Fator de Necrose Tumoral alfa/análiseRESUMO
Peripheral blood progenitor cell autografts are being used increasingly in conjunction with high-dose therapy of cancer patients, in the belief that these products have a low probability of containing tumor cells. However, recent findings demonstrate that tumor cell involvement is frequent in leukapheresis products. Although the clinical value of purging has not been clinically established by prospective randomized trials, several studies indicate that contaminating tumor cells in autografts contribute to relapse of the disease in the recipients. We describe our experimental and clinical experience in purging tumor cells from leukapheresis products. Based on our work with purging of lymphoma cells from bone marrow by the use of anti-B cell and anti-T cell antibodies and immunobeads, a purging procedure to deplete leukapheresis products of lymphoma cells has been developed. Moreover, we present data showing that breast cancer cells can be efficiently removed from leukapheresis products using antibreast cancer antibodies, either in combination with immunobeads or as immunotoxins. Our experience with enrichment of CD34 cells employing immunobeads in leukaphresis products from patients with breast cancer and lymphomas shows high purity and yield of CD34 cells. In spite of this, contaminating tumor cells can be observed, strongly suggesting that a combination of CD34 cell enrichment and a purging procedure might be warranted.
Assuntos
Purging da Medula Óssea/métodos , Leucaférese/métodos , Células Neoplásicas Circulantes , Anticorpos Monoclonais/imunologia , Antígenos de Diferenciação/análise , Antígenos de Neoplasias/análise , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Preservação de Sangue , Neoplasias da Mama/sangue , Neoplasias da Mama/patologia , Neoplasias da Mama/terapia , Terapia Combinada , Feminino , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Transplante de Células-Tronco Hematopoéticas/métodos , Humanos , Separação Imunomagnética , Subpopulações de Linfócitos , Linfoma/sangue , Linfoma/tratamento farmacológico , Linfoma/patologia , Linfoma/terapia , Masculino , Microesferas , Neoplasias/sangue , Neoplasias/terapia , Ensaios Clínicos Controlados Aleatórios como Assunto , Transplante AutólogoRESUMO
In this article we report our initial clinical experiences in connection with immunomagnetic isolated CD34-positive cells from peripheral blood progenitor cells. Six patients, five with breast cancer and one with non-Hodgkin's lymphoma, were mobilized by chemotherapy and G-CSF (5ug/kg). CD34-positive cells were isolated by means of immunomagnetic beads (Dynalbeads) and Isolex 300 Cell Separator (Baxter, USA). Mean purity of isolated CD34-positive cells was 97% (94.7-99.7) and mean yield was 54% (35-68). Three patients were treated with high dose therapy followed by reinfusion of CD34-positive cells as stem cell support. Recovery of neutrophils (> 0.5 x 10(9) leucocytes/liter) occurred at day 8, 11 and 13 and of platelets (> 20 x 10(9) platelets/litre) at day 9,14 and 32. It is concluded that immunomagnetic isolated CD34-positive cells give high purity and yield. Although use of CD34-positive cells reduces the content of contaminating tumour cells in the graft, breast cancer cells were still detectable in two out of five CD34-positive cell products.